Earnings ·
Telix Pharmaceuticals reported Q2 2026 revenue of US$247 million, representing a 21% year-over-year increase
TLPPFTelix Pharmaceuticals Ltd
Telix Pharmaceuticals reported Q2 2026 revenue of US$247 million, representing a 21% year-over-year increase. The company updated its FY 2026 revenue guidance to exceed US$1 billion and increased its R&D expenditure guidance to between US$230 million and US$270 million. Key developments include a strategic collaboration with Regeneron and a US$600 million convertible bond refinancing. Telix Pharmaceuticals is a commercial-stage global radiopharmaceutical company developing targeted theranostics for cancer treatment.